Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 8 Saturday Sunday Monday MONDAY, DECEMBER 9 TH 6:00pm - 8:00pm Pacific Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 5046 Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy Derman BA Essell JH Health Services and Quality Improvement: Lymphoid Malignancies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4200 NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival Valtis YK Battiwalla M, Majhail N, Malik S, Mountjoy L, Mathews J, Shaughnessy P Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4632 Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies Shadman M Levy MY, Zhang B, Burke JM, Cultrera JL, Yimer HA, Kingsley EC, Sharman JP Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4398 Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry Landsburg DJ Tees MT Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4753 Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): Updated Results Rifkin R Rifkin R, Schade H, Yasenchak C, Xu W Multiple Myeloma: Pharmacologic Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4734 Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study van de Donk NW Matous JV Multiple Myeloma: Pharmacologic Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4749 Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial Matous JV Matous JV Multiple Myeloma: Pharmacologic Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4757 In-class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received Richter J Rifkin R Multiple Myeloma: Pharmacologic Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4954 Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease Frangoul H Frangoul H Gene Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4955 Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial Hanna R Frangoul H Gene Therapies: Poster III